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squamous cell carcinoma of the head and neck (SCCHN) who 
are treated with combined chemoradiation (CRT). The aim 
was to find a potential SUVmax threshold to predict risk of 
distant failure (DF), local failure (LF) and regional failure 
(RF). This may help identifying patients at risk and subject 
them to intensified treatment. 
Materials and Methods: In a study conducted between 2008 
and 2014, 21 patients were prospectively analyzed for 
dynamics of tumor hypoxia during CRT. This consisted of 
radiotherapy in IMRT-technique (5 x 2 Gy/week up to 70 Gy) 
and concurrent platinum-based chemotherapy (weeks one, 
four and seven). Additionally the patients received 
pretreatment FDG-PET and MRI scans of the head and neck 
and FMISO-PET. The SUVmax determined in the FDG-PET/CT 
were used for further analysis to find a correlation with DF, 
LF and RF. In follow-up (FU) we performed regular CT and 
MRI scans of the head and neck and lung. For correlation 
analysis we used Spearman coefficient. We performed 
statistical analysis with SPSS Statistics 21 (IBM). 
Results: Between 08/2008 and 04/2014, 22 patients (three 
women and nineteen men) with histologically proven SCCHN 
were recruited, mean ECOG score 1, average FU time was 
30.6 months (0.6-63 months). Two patients developed DF (9.1 
%), five patients developed local (22.3 %) and two patients 
regional failure (9.1 %), respectively. The correlation 
coefficient between DF, LF, RF and FDG-SUVmax was -0.061, -
0.26 and 0.06, respectively. Median SUVmax in FDG-PET was 
14.4 (n=20). Average FDG-SUVmax of patients with any 
treatment failure (DF, LF and RF) was 15.2 (n=7).  
Conclusions: There could not be shown a significant 
correlation between DF, LF or RF and SUVmax in FDG-PET. But 
still our data shows that above an FDG-SUVmax of 14.4, a 
larger proportion of patients showed treatment failure, so 
there may be a higher risk for failure above that threshold. It 
remains an interesting question whether a larger cohort and 
a longer FU- time might show a correlation. There is need for 
further investigation.  
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Purpose/Objective: Tumor hypoxia is commonly related to a 
poorer prognosis and to higher radioresistance. The degree of 
reoxygenation during radiotherapy contributes to improved 
therapy success. 18-Fluoromisonidazole PET/CT (FMISO-PET) 
non-invasively allows visualizing tumor hypoxia and its 
dynamics under chemoradiation (CRT) of squamous cell 
cancer of the head and neck (SCCHN). There is little evidence 
for the relation between hypoxia and changes in blood 
oxygenation determined by hemoglobin (HB) and 
erythropoietin (EPO) levels in blood. Matter of interest is also 
the relation between these biomarkers with metastasis-free 
survival (MFS) and loco-regional control (LRC). 
Materials and Methods: Between 2008 and 2014 we 
prospectively analyzed the dynamics of tumor hypoxia during 
CRT in 21 patients at our center. This consisted of 
radiotherapy in IMRT-technique (5 x 2 Gy/week up to 70 Gy) 
and concomitant platinum-based chemotherapy (weeks one, 
four and seven). Additionally the patients received 
pretreatment FDG-PET and MRI scans of the head and neck 
and FMISO-PET for hypoxic imaging (in week 'zero'). The 
hypoxia was further evaluated in week 2 and 5 with two more 
FMISO-PET scans. EPO and HB levels were also determined 
parallel to hypoxic imaging. Tumor hypoxia in FMISO-PET was 
defined as SUVmax(tumor)/SUVmean(muscle). In follow-up (FU) 
we performed regular CT and MRI scans of the head and neck 
and lung. For correlation analysis we used Spearman 
coefficient. We performed statistical analysis with SPSS 
Statistics 21 (IBM). 
Results: Between 08/2008 and 04/2014, 22 patients (three 
women and nineteen men) with histologically proven SCCHN 
were recruited, mean ECOG score 1, average FU time was 
30.6 months (0.6-63 months). 4 patients developed DF (18.2 
%). Average SUVmax(tumor)/SUVmean(muscle) was 1.9/1.6/1.3 
(weeks 0/2/5; n=22/20/17). Average SUVmax in FDG-PET was 
14.4 (n=20). Average HB-concentrations were 14.1/12.6/10.9 
g/dl (weeks 0/2/5). Average EPO-concentrations were 
determined in 9 patients (7.3 mU/ml). Correlation coefficient 
between DF and FMISO- SUVmax(tumor)/SUVmean(muscle) is -
0.3/-0.4/-0.4 (in weeks 0/2/5). Correlation coefficient 
between HB and EPO, and between HB and FMISO is -0.02 and 
0.02/-0.3/-0.4 (weeks 0/2/5), respectively. 
Conclusions: There could not be shown any significant 
correlation between tumor hypoxia and HB and/or EPO, nor 
were there any correlations between distant failure and 
SUVmax(tumor)/SUVmean(muscle). There is need for further 
data acquisition.  
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Purpose/Objective: In cases of head and neck cancer (HNC) 
radiotherapy, custom-designed oral prostheses are sometimes 
used to depress the tongue or push the hard palate away 
from the clinical target volume (CTV) and intended to reduce 
side-effects to surrounding organs at risk (OAR). We 
evaluated whether the use of custom-designed oral 
prostheses improved daily setup precision of HNC.  
Materials and Methods: The custom-designed oral prostheses 
were made of resin to fit each patient’s oral cavity. The 
upper and lower parts and inter-space bar of the prostheses 
mate together by occlusal pressure to immobilize and 
displace the hard palate or tongue to reduce unnecessary 
radiation dose. Nine locally advanced HNC patients 
(prostheses group) at our hospital were treated from June 
2012 to September 2013 by three-dimensional external 
radiotherapy using custom-designed oral prostheses, 
immobilized with a thermoplastic mask. These patients 
(oropharyngeal: 4; tongue: 3; and maxillary: 2; histologically, 
7 squamous cell carcinoma (SqCC), and 2 lymphomas) 
received total doses of 50.4 to 68.4Gy (mean 58.8Gy) in daily 
fractions of 1.8 to 2.0 Gy. The seven patients with SqCC 
received concurrent chemotherapy of CDDP and 5-FU. Each 
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patient’s daily setup error was calculated as corrected shift 
distance by orthogonal electronic portal imaging device 
(EPID) and the target point marker on the thermoplastic 
mask. Each patient’s average of daily setup error size of 
medial-lateral (x), anterior-posterior (y) and cranial-caudal 
(z) axes was compared with that of 21 HNC patients (non-
protheses group) who did not use custom-designed oral 
prostheses during the same period. The non-prostheses group 
( pharyngeal: 11; oral cavity: 3; larynx: 3; thyroid: 2; and 
salivary gland: 2; histologically, 15 SqCC, 4 adenocarcinomas, 
and 2 lymphomas) received total doses of 45 to 70.0 Gy 
(mean 60.4 Gy) in fractions of 1.8 to 2.0 Gy per day. 18 of 
these patients (excepting 1 adenocarcinoma and 2 
lymphomas) received concurrent chemotherapy.  
Results: All patients tolerated the treatment, although they 
experienced grade 2 to 3 microsites, dermatitis and 
leukocytopenia. The average daily setup error for each 
prostheses group patient was less than that for the non-
prostheses group ( (x); 0.8 mm vs. 1.4 mm, (y); 0.7 mm 
vs.1.0mm, and (z); 0.8 mm vs. 1.3mm, respectively). Mean of 
(x) error with oral prostheses patients showed a significant 
difference (p=0.03). In addition, 3D-displacement (mean of 
sum squares of x, y, z) of prostheses group patients was less 
than that of non-prostheses group (5.0 vs.9.5, p=0.01). 
Conclusions: Custom-designed oral prostheses are self-
wearable safe devices. Use of custom-designed oral 
prostheses in HNC patients can reduce unnecessary radiation 
to OAR, and also provide better daily setup. More detailed 
evaluation in a larger patient population is desired in the 
future. 
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Purpose/Objective: A prospective trial investigated 
feasibility of a three-phase adaptive radiotherapy scheme 
using 18F-FDG-PET-CT guided dose-painting-by-numbers 
(DPBN) IMRT for head-and-neck cancer. We previously 
reported feasibility and clinical results upto 3 months. We 
now report on long-term locoregional (LRC) and distant 
control, overall survival (OS) and late toxicity. 
Materials and Methods: Ten patients with squamous cell 
carcinoma of the head and neck received primary 
radio(chemo)therapy using DPBN. All patients received 3 
consecutive phases of 10 fractions for in total 6 weeks. 18F-
FDG-PET-CT guided DPBN was planned beteen 2.0 – 3.5 Gy 
per fraction to the GTV (fractions 1-10) and 2.0-2.5 Gy 
(fractions 11-30). The elective neck was treated at 2.0 
Gy/fraction (fractions 1-20). Repeated 18F-FDG-PET-CT after 
fractions 8 and 18 were used to plan phase 2 and 3, 
respectively. Concomitant cisplatin at days 1-22-43 at 100 
mg/m² was prescribed in 4 patients. All patients underwent 
multidisciplinary assessment of disease control and late 
toxicity at months 1-3-6-9-12-16-20-24-30-36 after 
treatment. We analysed local, regional and distant control 
and survival; for toxicity evaluation we analysed all grades of 
late dysphagia, xerostomia and mucosal integrity problems as 
well as any other grade ≥ 3 late toxicity at 6, 12, 24 and 36 
months.  
 
Results:  
 
Patient and tumor characteristics can be found in Table 1.  
